日韩精品无码一区二区三区免费,在线观看欧美一区,高清国产免费观看,久久久久精品视频,免费观看国产小粉嫩喷水,久久播放无码专区

產(chǎn)品資料

Erlotinib, Hydrochloride Salt **

如果您對該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱: Erlotinib, Hydrochloride Salt **
產(chǎn)品型號: LC E-4007
產(chǎn)品展商: 原裝進(jìn)口
產(chǎn)品文檔: 無相關(guān)文檔

簡單介紹

Erlotinib, Hydrochloride Salt **


Erlotinib, Hydrochloride Salt **  的詳細(xì)介紹
Erlotinib, Hydrochloride Salt **

產(chǎn)品名稱:Erlotinib, Hydrochloride Salt
產(chǎn)品貨號:LC  E-4007 
產(chǎn)品規(guī)格:10 G
Inhibitor of the epidermal growth factor receptor tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer.  Erlotinib binds reversibly to the ATP binding site of the receptor.  Raymond, E., et al.  "Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy."  Drugs 60 Suppl 1:  15-23, discussion 41-42 (2000).
Erlotinib is an inhibitor of human EGFR tyrosine kinase (IC50 = 2 nM) and decreases EGFR autophosphorylation in tumor cells (IC50 = 20 nM).  Moyer, J.D., et al.  "Induction of Apoptosis and Cell Cycle Arrest by erlotinib, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase."  Cancer Res. 57:  4838-4848 (1997).
Erlotinib has been shown to be a potent inhibitor of JAK2-V617F, a mutant of tyrosine kinase JAK2 found in a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia and most patients with polycythemia vera (PV).  The study indicates that erlotinib may be used to treat JAK2-V617F-positive PV and other myeloproliferative disorders.  Li, Z., et al. "Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth."  J. Biol. Chem. 282:  3428-3432 (2007).
Found to be a potent inhibitor of EGFR kinase (Ki = 0.7 nM), but much weaker for ErbB-2 kinase (Ki = 1 µM) and ErbB-4 kinase (Ki = 1.5 µM).  Wood, E.R., et al.  "A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib), Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells."  Cancer Res. 64:  6652-6659 (2004).
Erlotinib is the active ingredient in the drug sold under the trade name Tarceva®.  This drug has been approved in at least one country for use in patients with pancreatic cancer, non-small cell lung cancer and several other types of cancer.  NOTE:  THE ERLOTINIB, HYDROCHLORIDE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT TARCEVA®, AND IS NOT FOR HUMAN USE.
Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 18 mg/mL with warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

產(chǎn)品留言
標(biāo)題
聯(lián)系人
聯(lián)系電話
內(nèi)容
驗(yàn)證碼
點(diǎn)擊換一張
注:1.可以使用快捷鍵Alt+S或Ctrl+Enter發(fā)送信息!
2.如有必要,請您留下您的詳細(xì)聯(lián)系方式!
使用指南 付款方式 客戶關(guān)懷 **與保密 法律幫助 服務(wù)條款 監(jiān)察中心信箱
分享到:

滬公網(wǎng)安備 31011002002623號